Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Core Insights - Trevi Therapeutics, Inc. has appointed David Hastings as the new Chief Financial Officer effective January 6, 2026, to lead financial strategy and support the company's growth phase [1][2][3] Company Overview - Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [1][4] - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC patients [4] Market Need - There are approximately 150,000 patients with IPF in the U.S., with two-thirds experiencing uncontrolled chronic cough, and around 228,000 patients with non-IPF ILD, with 50-60% also suffering from uncontrolled chronic cough [5] - RCC affects an estimated 2-3 million patients in the U.S. and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [6] Leadership Experience - David Hastings brings over 25 years of financial leadership in life sciences and biopharmaceuticals, having raised over $2 billion in equity and debt financing throughout his career [2] - His previous roles include CFO at Arbutus and Incyte, where he managed financial operations during significant transitions and commercialization phases [2][3] Strategic Importance - Hastings' experience is deemed critical as Trevi transitions into Phase 3 development for Haduvio, with a focus on advancing the treatment for chronic cough [3] - The company is positioned with statistically significant data across target indications, limited competition, and a strong cash position, which are expected to enhance long-term value for patients and shareholders [3]